Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mass Balance Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Human Mass Balance Study of HMS5552 in Healthy Subjects

NCT03158506
View directory record Official record
Conditions
Healthy Subject
Interventions
HMS5552
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Mass Balance Study

NCT00828763
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14c}-GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Jul 21, 2026, 5:28 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

NCT01273103
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
200mg [14C]- GSK2248761
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
30 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX

NCT01367483
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
IV methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293

NCT02126514
View directory record Official record
Conditions
Healthy Volunteers, Mass Balance Study
Interventions
AZD3293
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

NCT01299285
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3009104
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-9855 Mass Balance Study

NCT01924143
View directory record Official record
Conditions
ADHD, Fibromyalgia
Interventions
TD-9855
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

NCT04454918
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

NCT06886269
View directory record Official record
Conditions
Pain
Interventions
14C-VX-993
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

NCT04225208
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-AZD4205, single 50 mg oral dose administrated on day 1
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men

NCT07314320
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-OPC-167832
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects

NCT02059590
View directory record Official record
Conditions
Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate, Healthy Subjects
Interventions
Pyridinylmethyl-14C-labeled isavuconazonium sulfate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

NCT05406817
View directory record Official record
Conditions
Acute Leukemia
Interventions
Revumenib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

NCT01469481
View directory record Official record
Conditions
Healthy
Interventions
PF-04991532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mass Balance Study of KBP-5074 in Healthy Male Subjects

NCT04634812
View directory record Official record
Conditions
Healthy
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Terminated Phase 1 Interventional

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

NCT03804515
View directory record Official record
Conditions
Solid Tumor
Interventions
14C-labeled poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606

NCT00757341
View directory record Official record
Conditions
Healthy Subjects
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2009 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

NCT02110342
View directory record Official record
Conditions
Healthy
Interventions
[14C] PF-04449913
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Mass Balance Study of Varegacestat

NCT06845852
View directory record Official record
Conditions
Healthy Volunteer
Interventions
varegacestat
Drug
Lead sponsor
Immunome, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

NCT06414798
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Drug: ABBV-1088, Drug: Placebo for ABBV-1088
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 21, 2026, 5:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

NCT04655898
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]CC-90001
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 21, 2026, 5:28 PM EDT